jueves, 31 de enero de 2019

Roche’s Alzheimer’s failure increases tension for Biogen - STAT

Roche’s Alzheimer’s failure increases tension for Biogen - STAT

Daily Recap

STAT Plus: Roche’s Alzheimer’s failure increases tension for Biogen

By MATTHEW HERPER


NATIONAL INSTITUTE ON AGING, NIH
The news is not weighing on Roche's stock, but it is weighing on Biogen, which is betting its future on another beta-amyloid-targeting drug.

No hay comentarios:

Publicar un comentario